|
Match
|
Document |
Document Title |
|
|
6673367 |
Controlled/modified release oral methylphenidate formulations
The invention is directed to oral modified/controlled release methylphenidate formulations which provide a rapid initial onset of effect and a prolonged duration of effect. Preferably, the peak...
|
|
|
6673372 |
Crystalline Efavirenz
The potent reverse transcriptase inhibitor Efavirenz is produced in crystalline form. Crystalline Efavirenz exists in several physical forms which are-designated Forms 1, 2, 3 and 4, and are...
|
|
|
6670038 |
Method of depositing particles with an electrostatic chuck
The present invention is directed to electrostatic chucks, methods for their use, the electrostatic deposition of objects, such as particles in a dry powder, onto recipient substrates, and the...
|
|
|
6669955 |
Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally...
|
|
|
6669956 |
Tablets incorporating isoflavone plant extracts and methods of manufacturing them
The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
|
|
|
6669954 |
Controlled release of drugs
A device for controlled release of pharmaceutical agents and a method for use of the device. The drug delivery device comprises a covered container with an aperture and an aperture cover,...
|
|
|
6669952 |
Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol
A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally...
|
|
|
6669957 |
Galenic formulations fast disintegrating in the mouth and method for preparing same
The invention relates to pharmaceutical dosage forms with rapid disintegration in the mouth and to their process of preparation. These pharmaceutical dosage forms comprise at least one active...
|
|
|
6667057 |
Levofloxacin antibiotic product, use and formulation thereof
An antibiotic product, in particular levofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being...
|
|
|
6667054 |
Metformin hydrochloride tablets
Tablets for oral administration comprising metformin hydrochloride and methylcellulose.
|
|
|
6667042 |
Fluroquinilone antibiotic product, use and formulation thereof
An antibiotic product, in particular a fluroquinilone such as ciprofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the...
|
|
|
6667055 |
Filler binder for tablets
The invention relates to a novel filler-binder for tablets, which shows a significantly reduced lubricant sensitivity when compared to prior art filler-binders. The invention further relates to a...
|
|
|
6667060 |
Pregelatinized starch in a controlled release formulation
The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release...
|
|
|
6667050 |
Chewable oral contraceptive
The present invention relates to a chewable, palatable oral contraceptive tablet, comprising an oral contraceptive agent, a chewable carrier suitable for human consumption, and not comprising a...
|
|
|
6663897 |
Oral itraconazole formulations and methods of making the same
A method of manufacturing an itraconazole oral dosage form that is substantially free of residual methylene chloride comprises the steps of: (a) providing a working solution comprising an alcohol,...
|
|
|
6663890 |
Metronidazole antibiotic product, use and formulation thereof
An antibiotic product, in particular metronidazole, is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being...
|
|
|
6663891 |
Erythromyacin antibiotic product, use and formulation thereof
An antibiotic product, in particular an erythromyacin, is comprised of at least three dosages forms, each of which has a different release profile, with the C max for the antibiotic product being...
|
|
|
6663889 |
Ambroxol-containing lozenge
The present invention relates to a new tablet for sucking containing the active substance ambroxol and having improved properties.
|
|
|
6663892 |
Multiple portion tablet
A solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H 2 -receptor...
|
|
|
6663893 |
Taste masking coating composition
There is provided a coating composition that masks the undesirable taste of a pharmaceutically active ingredient, i.e. drug or medicine, that is taken orally. The coating composition is comprised...
|
|
|
6663884 |
Method of detoxifying the egg of puffer fish for creating healthy foodstuffs and the resulting product
A method of detoxifying the egg of puffer fish for creating healthy foodstuffs which includes the steps of heating the eggs of puffer fish and ginger root at a temperature of 100-200° C. for 30-40...
|
|
|
6660303 |
Pharmaceutical superdisintegrant
Superdisintegrants which provide improved compressibility compared to prior art superdisintegrants and which does not negatively impact the compressibility of formulations which include high-dose...
|
|
|
6660298 |
Paroxetine tablets and capsules
Method for preparing a wet granule formulation of paroxetine hydrochloride are disclosed. The formulations are suitable for tabletting and capsulation.
|
|
|
6660297 |
Nutritional supplement to treat macular degeneration
A nutritional or dietary supplement composition that strengthens and promotes retinal health through the prevention, stabilization, reversal and/or treatment of visual acuity loss by reducing the...
|
|
|
6656502 |
Sustained-release prostaglandin I derivative preparation
A sustained release preparation of prostaglandin I derivatives, which is highly safe and has stable drug-releasing and absorption properties, is disclosed. In the orally administrable preparation,...
|
|
|
6656485 |
Products for body hygiene based on lapacho extracts containing quercitine, their preparation and use
Products for body hygiene containing Lapacho extracts and also quercitine and possibly other quinones present in Lapacho extracts salified or whatever modified in order to make them soluble in...
|
|
|
6656920 |
Composition and method for promoting oral health
The present invention relates to a method for increasing unstimulated whole saliva in a patient. The method comprises orally administering an effective amount of a disaccharide, such as maltose,...
|
|
|
6656503 |
Pharmaceutical tablet comprising an NSAID and misoprostol
A pharmaceutical tablet comprising a core and a film coating wherein the core comprises an NSAID and the film coating comprises a polymer and misoprostol.
|
|
|
6652866 |
Method for treating diseases of fungal, yeast, and prion protein etiology
A method for treating neurological diseases in mammals comprising the step of administering a mixture comprising selected carboxylic acids in an effective amount for treating the neurological...
|
|
|
6652838 |
Method for treating diabetes mellitus
A method for treating postprandial hyperglycemia in diabetes mellitus in a human which employs a combination of an aerosolizable topical insulin and a short-acting oral hypoglycemic agent as a...
|
|
|
6649183 |
Methods for treating apnea and apnea disorders using optically pure R(&plus ) ondansetron
Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or...
|
|
|
6649187 |
Use of polyalkylamine polymers in controlled release devices
The invention provides a method and device for administering an amine drug, such as...
|
|
|
6645526 |
Storage stable thyroxine active drug formulations and methods for their production
This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an...
|
|
|
6645523 |
Paroxetine compositions and processes for making the same
Paroxetine salt compositions having improved stability are formed by controlling the pH to 6.5 or less. The compositions can be made with the aide of water without significant coloration problems....
|
|
|
6645482 |
Proteoglycan compositions for treating arthritic inflammatory conditions
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory...
|
|
|
6645524 |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and...
|
|
|
6642201 |
Use of a dipeptide for stimulating repair processes
L-Lys-L-Glu dipeptide is proposed for use in medicine for preparation of a drug capable of stimulating repair processes. According to the invention, the pharmaceutical peptide preparation capable...
|
|
|
6642276 |
Controlled release macrolide pharmaceutical formulations
Disclosed is an oral controlled release macrolide pharmaceutical formulation. In a preferred embodiment, the formulation comprises a citrate salt of a preferred macrolide, clarithromycin. Also...
|
|
|
6641840 |
Sustained release formulations for growth hormone secretagogues
The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a...
|
|
|
6638531 |
Antimicrobial peptides
The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of...
|
|
|
6638498 |
Molecularly imprinted polymers for the treatment and diagnosis of medical conditions
Improved molecularly imprinted polymers (MIPs) with both higher and more specific binding capacity for particular bile acids and/or salts, including the synthesis of such MIPs, the compounds...
|
|
|
6638521 |
Oral liquid mucoadhesive compositions
The present invention relates to a per oral, oral, or intranasal pharmaceutical mucoretentive, aqueous liquid composition comprising from about 2% to about 50%, by weight of the composition, of...
|
|
|
6638522 |
Microemulsion concentrate composition of cyclosporin
The present invention is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of Cyclosporin, in association with a pharmaceutical carrier, said carrier...
|
|
|
6638535 |
Modified release formulations containing a hypnotic agent
Hypnotic pharmaceutical compositions are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably...
|
|
|
6638532 |
Tetracycline—doxycycline antibiotic composition
An antibiotic product for delivering at least Tetracycline or Doxycycline that is comprised of three dosage forms with different release profiles with each of Tetracycline and Doxycycline being...
|
|
|
6635278 |
Pharmaceutical formulations
The invention provides compositions comprising the nucleotide analog 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adeni
ne and an alkaline excipient with or without...
|
|
|
6635280 |
Extending the duration of drug release within the stomach during the fed mode
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to...
|
|
|
6635625 |
Proteoglycan compositions for treating prostate and bladder inflammatory conditions
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory...
|
|
|
6635281 |
Gastric retaining oral liquid dosage form
The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid...
|
|
|
6632451 |
Delayed total release two pulse gastrointestinal drug delivery system
A two pulse gastrointestinal delivery system is provided. The system comprises a desired agent in combination with a swellable core material, the core being surrounded by an inner coat of a...
|